Clear Cell Renal Cell Carcinoma

Publication Date: October 9, 2023

Key Points

Key Points

  • Kidney cancer will be diagnosed in 79,000 U.S. patients in 2022 and will account for 13,920 deaths.
  • Opportunities for extended survival and even durable disease control in the metastatic setting have recently appeared as novel classes of therapeutics, reshaping the trajectory of this cancer.
  • This rapid evolution has paved the way for this first set of comprehensive guidelines for treating metastatic clear cell renal cell carcinoma (ccRCC).

Diagnosis

...Diagnosis...

...dation 1.1The diagnosis of metastatic cle...


...ommendation 1.2Radiographic diagnosis of metasta...


Treatment

...Treatment

...commendation 2.1Select patients (see Pract...


...on 3.1Select patients with metastatic clear cell...


...-Line Treatmenta Select cases (see Recom...


...ndation 3.2All patients with metastatic clea...


...ation 3.3Patients with favorable risk disease wh...


...ecommendation 3.4Select patients with metastat...


...ecommendation 3.5The use of high dose...


...Re...

...endation 3.6Treatment with IpiNivoCabo is not...


...ation 4.1Nivolumab or cabozantinib should be of...


...4.2Patients progressing on combination immun...


...ndation 4.3Patients who progress aft...


...4.4For patients on immunotherapy w...


...n 5.1For patients with low volume...


....2For patients undergoing complete met...


....1.1Patients with symptomatic bone metastases fro...


...n 6.1.2Patients with bone metastases from met...


...Second-Line or Greater Treat...


...3. Metastases-Directed Treatment...


....1.3No recommendation regarding optimal syste...


...ommendation 6.2.1Patients with bra...


...n 6.2.2No recommendation regarding op...


...mmendation 6.3Patients with metastatic...


...4. Special Patient Subtypes...


...believes that cancer clinical trials are v...